Strategic Acquisition Enhances AI Capabilities
ScreenPoint Medical’s acquisition of Biomediq A/S on January 8, 2025, represents a milestone in AI-driven breast cancer detection. This strategic merger follows ten years of collaborative research, integrating Biomediq’s quantitative…
What You Should Know:
– ScreenPoint Medical, a provider of AI-powered breast cancer screening solutions, acquires Biomediq A/S, a research-based company specializing in quantitative imaging biomarkers. Financial details of the acquisition were not disclosed.
– ScreenPoint’s…
Continue Reading
Introduction
The Transpara Breast AI system is transforming breast cancer screening by delivering unmatched diagnostic precision and reducing false negatives. Developed with cutting-edge artificial intelligence, Transpara assists radiologists in detecting cancers that might otherwise go…
Transforming breast cancer detection, ScreenPoint Medical’s Transpara Breast AI integrates seamlessly into Johns Hopkins Medicine’s renowned breast imaging services. This collaboration harnesses cutting-edge technology and clinical expertise to enhance screening accuracy and patient outcomes….
Continue Reading
Discover how Transpara Breast AI by ScreenPoint Medical revolutionizes mammography screening by providing radiologists with advanced support in cancer detection. Through real-world clinical studies presented at the European Congress of Radiology, learn how Transpara…
Continue Reading
